Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the growth of breast cancer cell growth in vitro, its impact on the treatment a...

Descripción completa

Detalles Bibliográficos
Autores principales: Varikuti, Sanjay, Singh, Bhawana, Volpedo, Greta, Ahirwar, Dinesh K., Jha, Bijay K., Saljoughian, Noushin, Viana, Agostinho G., Verma, Chaitenya, Hamza, Omar, Halsey, Gregory, Holcomb, Erin A., Maryala, Ritvik J., Oghumu, Steve, Ganju, Ramesh K., Satoskar, Abhay R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109110/
https://www.ncbi.nlm.nih.gov/pubmed/32025027
http://dx.doi.org/10.1038/s41416-020-0743-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109110/
https://www.ncbi.nlm.nih.gov/pubmed/32025027
http://dx.doi.org/10.1038/s41416-020-0743-8

Ejemplares similares